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Following the recent advances in cardiac stem cell biology,
cardiac tissue has become one of the targets of regenerative
medicine. With the array of approaches that are currently
being tested and the questions that they raise, it becomes
increasingly clear that the regeneration of adult myocardium
will require the integration of numerous factors that govern
cardiac tissue biology in normal and pathological conditions.
e current challenge in myocardial tissue engineering and
regeneration is to establish a perfect combination of three
components: cells, scaffolds, and signaling molecules [1].
Since the recognition that the mammalian heart is char-
acterized by cardiomyocyte turnover throughout the lifespan
of an individual, a number of different cardiac stem cell
populations have been identi�ed in the postnatal and adult
hearts. A desirable candidate cell for cardiac tissue engi-
neering and regeneration would be autologous, capable of
differentiation into all the cardiac cell types and of functional
integration, and resistant to malignant transformation. e
preclinical studies and clinical trials have employed different
cell types, including embryonic stem cell-derived and fetal
cardiomyocytes, skeletal myoblasts, bone marrow or periph-
eral blood-derived endothelial progenitors, haematopoietic
and mesenchymal stem cells, and recently, reprogrammed
adult somatic cells (induced pluripotent stem cells). ese
multiple cell choices, apart from being accompanied by
important ethical and safety concerns, led to a rather uniform
outcome, which consisted of a low degree of improvement in
cardiac contractile function. Moreover, a regenerated tissue
band, which would integrate functionally with the surviving
myocardium, was observed only in few cases [2].
e choice of cell population for myocardial regeneration
should be based on the knowledge of stem cell biology and
the mechanisms that regulate and control cardiac progenitor
proliferation, apoptosis, and differentiation in the normal
and pathological conditions [3]. Recently, short noncoding
RNAs, named micro-RNAs (miRs), have been found to
control gene expression by blocking mRNA translation and
inducing its degradation. MiR-1 was among the �rst in this
group that had been identi�ed as regulators of muscle cell
proliferation and differentiation [4]. In this special issue, F.
Huang et al. demonstrated that the downstream molecular
target of Notch, Hes-1, decreased, while the expression of
speci�c cardiac genes increased, in mesenchymal stem cells
infected with lentiviral vectors carrying miR-1. is miR
may be useful for stimulation of cell fate decision towards
cardiomyocyte lineage.
e group of M. �. Roehrich et al. identi�ed by �ow
cytometry yet another stem cell population, with high expres-
sion and activity of aldehyde dehydrogenase (ALDH), in the
adult heart, and the results of the characterization of these
cells are published for the �rst time in the present special
issue. is population is enriched for cells expressing Sca-1,
CD34, CD90, CD44, and CD106, which indicates that it is
a heterogeneous cell population, and presents mesenchymal
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stem cell-like differentiation potential. Interestingly, ALDH
bright cells had been already sorted from human cord
blood, bone marrow and peripheral blood and identi�ed in
nonhaematopoietic tissues as neural, muscle, colonic, and
mammary stem cells. e activity of this enzyme allows
cells to survive oxidative stress and can in�uence numerous
functions that are crucial for stem cell survival in hypoxic
environment. Indeed, cells with high activity of ALDH
homed to ischemic sites (in the infarcted heart and hind
limb ischemia model) and mediated local vasculogenesis
[5]. Recent preliminary results indicate that treatment with
ALDH bright autologous bone marrow cells is safe and
may provide functional bene�ts in patients with chronic
myocardial ischemia [6]. However, cell number and method
of delivery may in�uence the e�cacy of ALDH bright and all
other cell populations used for myocardial regeneration.
Many factors determine the outcome of regenerative
cardiovascular therapy and are the possible reasons behind
the variable results. In fact, the methods for cell isolation and
puri�cation, the procedures for their storage or propagation,
the phenotype and number of injected cells, and the methods
of cell administration are hugely inconsistent between stud-
ies. e current stem cell delivery methods for myocardial
repair are reviewed in the present special issue by C. C. Sheng
et al. e possibilities are continuously expanding and the
report of the International Society for Cardiovascular Trans-
lational Research, with the recommendations for the delivery
of stem cells that would be comparable between groups [7],
should be soon updated to include also bioengineered cardiac
tissue transplantation.
An ideal scaffold for tissue engineering must be biocom-
patible, allow cell growth and differentiation, and integrate
(or degrade in time-controlled manner) into the host tissue.
While patch-based scaffolds for cardiac regeneration must
reach the dimensions relative to infarct size in humans, com-
ply with the tension developed in the ventricular wall during
systole and diastole cycles, and still be applicable through
minimally invasive procedures, injectable scaffolds must be
able to pass through a small gauge catheter and reconstitute
their �brous structure through gelation. Preclinical studies
indicate that the combined cell-biomaterial scaffold therapy
is superior to cell therapy alone [8], but the evaluation of
cellular effects in vitro would be even more reliable and
easier to translate in clinical application if performed in 3D
culture platforms. 3D environment and high cell density
play an important role in supporting the phenotypes of
cells of cardiac lineages. Many of these aspects of scaffold
composition and cellular biology are discussed in this special
issue.
First, the original contribution of K. Vukusic et al.
describes the behaviour of cardiomyocytes, endothelial cells,
�broblasts, and c-kit-positive cardiac primitive cells in high
density sphere cultures. e simple method of sphere for-
mation and culture, starting from the pellet of cardiac cells
that rounded up and formed spherical structure that �oated
in the culture media, adds to the previously character-
ized methods of cardiosphere generation (hanging drop or
standard plate suspension culture). Growth of cardiac cells
as cardiospheres enhanced expression of stem cell-relevant
markers. Next, L. Ikonen et al. examined collagen-like syn-
thetic self-assembling nano�ber hydrogels for their suitability
for neonatal rat cardiomyocyte and human embryonic stem
cell-derived cardiomyocyte culture in 2D. Although the dif-
ferentiation of stem cells into cells of cardiac lineages in these
hydrogels would be more indicative of their application in
myocardial regeneration, it is of note that hydrogel was able to
maintain the beating ability of differentiated cardiomyocytes
in vitro. As such, it can represent a usefulmodel for preclinical
testing of cellular populations and stem cell-derived car-
diomyocytes for tissue engineering. In addition, the research
of D. Avitabile et al. offers the basis for a further optimization
of stem cell and scaffold processing for myocardium repair,
showing that embedding human cord blood-derived CD34+
cells into a collagen I-based hydrogel containing cytokines is
a suitable strategy to promote proliferation and protect these
cells fromhypoxia-induced apoptosis.e properties of these
injectable composites make them promising candidates for
myocardial tissue regeneration and warrant further studies
on their potential therapeutic application.
With these and other scienti�c advances in basic science
research, which provide clinicians with the tools for replacing
damaged myocardium, the concept of cardiac regeneration
should hopefully progress to a level that will allow the
translation and application of tissue engineering triad, that
is, cells, scaffolds, and signalling molecules, in the clinical
setting. e success of this integrated approach will depend
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